Last reviewed · How we verify
NCT04318327
BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma
Phase 1 trial testing PHE885 in Multiple Myeloma in 96 participants. Terminated before completion.
29 April 2025
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 96 |
| Start date | 23 July 2020 |
| Primary completion | 29 April 2025 |
| Estimated completion | 29 April 2025 |
| Sites | 9 locations across Israel, United States, Australia, Singapore |
Drugs / interventions tested
- PHE885 — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 18 to 100, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells were investigated as a single agent in multiple myeloma
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR T therapies in multiple myeloma: unleashing the future.
Sheykhhasan M, Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al · · 2024 · cited 109× · PMID 38438559 · DOI 10.1038/s41417-024-00750-2 -
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2 -
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges.
Rendo MJ, Joseph JJ, Phan LM, DeStefano CB. · · 2022 · cited 43× · PMID 36060553 · DOI 10.2147/blctt.s327016 -
CAR-T cell therapy in Multiple Myeloma: current status and future challenges.
Swan D, Madduri D, Hocking J. · · 2024 · cited 32× · PMID 39592597 · DOI 10.1038/s41408-024-01191-8 -
Culture expansion of CAR T cells results in aberrant DNA methylation that is associated with adverse clinical outcome.
Salz L, Seitz A, Schäfer D, Franzen J, et al · · 2023 · cited 26× · PMID 37452103 · DOI 10.1038/s41375-023-01966-1 -
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT, Ye JC. · · 2021 · cited 21× · PMID 34301270 · DOI 10.1186/s13045-021-01109-y -
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Abramson HN. · · 2023 · cited 16× · PMID 37958658 · DOI 10.3390/ijms242115674 -
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Lin CH, Tariq MJ, Ullah F, Sannareddy A, et al · · 2024 · cited 14× · PMID 38892379 · DOI 10.3390/ijms25116192
Verify or expand the search:
- PubMed search for NCT04318327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PHE885
Trials testing the same drug.
- NCT05172596 — PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma · Phase 2 · terminated
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04318327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04318327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing